Protalix repays all convertible notes, becomes debt-free; EMA validates Fabry drug dosing variation

Protalix BioTherapeutics, Inc.

Repaid in full all outstanding convertible notes, making company debt-free.
EMA validated Chiesi's variation submission for pegunigalsidase alfa every-four-week dosing in EU.
Completed Phase I trial of PRX-115 for uncontrolled gout; Phase II planned H2 2025.
Revenue streams from Elfabrio, Elelyso, and Uplyso growing; full operations maintained despite Israel conflict.
Fine-tuned R&D strategy on renal rare diseases and plant-based drug delivery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.